DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines.

Laboratory of Molecular Carcinogenesis, NIEHS, National Institutes of Health, Research Triangle Park, NC 27709, USA.
International Journal of Cancer (Impact Factor: 6.2). 03/2011; 130(2):267-77. DOI: 10.1002/ijc.26082
Source: PubMed

ABSTRACT Nonsteroidal anti-inflammatory drug-activated gene, NAG-1, a transforming growth factor-β member, is involved in tumor progression and development. The association between NAG-1 expression and development and progression of glioma has not been well defined. Glioblastoma cell lines have lower basal expression of NAG-1 than other gliomas and normal astrocytes. Most primary human gliomas have very low levels of NAG-1 expression. NAG-1 basal expression appeared to inversely correlate with tumor grade in glioma. Aberrant promoter hypermethylation is a common mechanism for silencing of tumor suppressor genes in cancer cells. In glioblastoma cell lines, NAG-1 expression was increased by the demethylating agent, 5-aza-2'-deoxycytidine. To investigate whether the NAG-1 gene was silenced by hypermethylation in glioblastoma, we examined DNA methylation status using genomic bisulfite sequencing. The NAG-1 promoter was densely methylated in several glioblastoma cell lines as well as in primary oligodendroglioma tumor samples, which have low basal expression of NAG-1. DNA methylation at two specific sites (-53 and +55 CpG sites) in the NAG-1 promoter was strongly associated with low NAG-1 expression. The methylation of the NAG-1 promoter at the -53 site blocks Egr-1 binding and thereby suppresses Nag-1 induction. Treatment of cells with low basal NAG-1 expression with NAG-1 inducer also did not increase NAG-1. Incubation with a demethylation chemical increased Nag-1 basal expression and subsequent incubation with a NAG-1 inducer increased NAG-1 expression. We concluded from these data that methylation of specific promoter sequences causes transcriptional silencing of the NAG-1 locus in glioma and may ultimately contribute to tumor progression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography (PET) with amino acid tracers is useful for the visualization and assessment of therapeutic effects on gliomas. Our purpose is to elucidate the transport mechanisms of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid (anti-[(18)F]FACBC) and l-[methyl-(11)C]methionine ([(11)C]Met) in normal human astrocytes (NHA), low-grade (Hs683, SW1088), and high-grade (U87MG, T98G) human glioma cell lines. Because the short half-lives of fluorine-18 and carbon-11 are inconvenient for in vitro experiments, trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid (anti-[(14)C]FACBC) and l-[methyl-(14)C]methionine ([(14)C]Met) were used instead of the PET tracers. Time-course uptake experiments showed that uptake of anti-[(14)C]FACBC was 1.4-2.6 times higher than that of [(14)C]Met in NHA and low-grade glioma cells, and was almost equal to that of [(14)C]Met in high-grade glioma cells. To identify the amino acid transporters (AATs) involved in the transport of anti-[(14)C]FACBC and [(14)C]Met, we carried out competitive inhibition experiments using synthetic/naturally-occurring amino acids as inhibitors. We found that anti-[(14)C]FACBC uptake in the presence of Na(+) was strongly inhibited by l-glutamine and l-serine (the substrates for ASC system AATs), whereas l-phenylalanine and 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid (BCH, the substrates for L system AATs) robustly inhibited Na(+)-independent anti-[(14)C]FACBC uptake. Regardless of Na(+), [(14)C]Met uptake was inhibited strongly by l-phenylalanine and BCH. Moreover, the exchange transport activity of l-glutamine for anti-[(14)C]FACBC was stronger than that of BCH in the presence of Na(+), whereas that for [(14)C]Met was almost equal to BCH. These results demonstrate that ASC and L are important transport systems for anti-[(18)F]FACBC uptake, while system L is predominantly involved in [(11)C]Met transport in human astrocytes and glioma cells.
    Brain research 08/2013; · 2.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1), a member of the transforming growth factor β (TGF-β) superfamily, has been demonstrated to possess antitumorigenic and proapoptotic activities in gastric cancer cells. In the present study, the expression of NAG-1 was assessed in human gastric carcinoma, tumor-adjacent normal tissues and normal gastric mucosa, with the aim to investigate the role of NAG-1 in the carcinogenesis and development of gastric carcinoma. NAG-1 protein expression was evaluated using immunohistochemical staining, while the expression of NAG-1 mRNA was evaluated using reverse transcription-polymerase chain reaction. It was observed that adenocarcinoma tissues had a lower expression of NAG-1 than normal gastric tissues. Furthermore, moderately and well-differentiated adenocarcinoma tissues expressed more NAG-1 protein than the poorly differentiated adenocarcinoma tissues. The expression of NAG-1 protein in adenocarcinoma tissues did not correlate with tumor-node-metastasis staging, infiltration degree or tumor size. The NAG-1 mRNA expression in adenocarcinoma tissues was also lower than that in normal gastric tissues. In conclusion, NAG-1 was poorly expressed in adenocarcinoma tissues and inversely correlated with the degree of tumor differentiation. These results indicate that NAG-1 may have an anti-oncogenic function in the carcinogenesis and development of gastric carcinoma, and that its attenuated or absent expression may lead to gastric carcinogenesis.
    Experimental and therapeutic medicine 01/2014; 7(1):241-245. · 0.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonsteroidal anti-inflammatory drug (NSAID) activated gene-1 (NAG-1) is a divergent member of the transforming growth factor-beta (TGF-β) superfamily. NAG-1 plays remarkable multifunctional roles in controlling diverse physiological and pathological processes including cancer. Like other TGF-β family members, NAG-1 can play dual roles during cancer development and progression by negatively or positively modulating cancer cell behaviors. In glioblastoma brain tumors, NAG-1 appears to act as a tumor suppressor gene; however, the precise underlying mechanisms have not been well elucidated. In the present study, we discovered that overexpression of NAG-1 induced apoptosis in U87 MG, U118 MG, U251 MG, and T98G cell lines via the intrinsic mitochondrial pathway, but not in A172 and LN-229 cell lines. NAG-1 could induce the phosphorylation of PI3K/Akt and Smad2/3 in all six tested glioblastoma cell lines, except Smad3 phosphorylation in A172 and LN-229 cell lines. In fact, Smad3 expression and its phosphorylation were almost undetectable in A172 and LN-229 cells. The PI3K inhibitors promoted NAG-1-induced glioblastoma cell apoptosis, while siRNAs to Smad2 and Smad3 decreased the apoptosis rate. NAG-1 also stimulated the direct interaction between Akt and Smad3 in glioblastoma cells. Elevating the level of Smad3 restored the sensitivity to NAG-1-induced apoptosis in A172 and LN-229 cells. In conclusion, our results suggest that PI3K/Akt and Smad-dependent signaling pathways display opposing effects in NAG-1-induced glioblastoma cell apoptosis.
    PLoS ONE 04/2014; 9(4):e96283. · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Jun 11, 2014